Voriconazole is not generally used to treat urinary tract infections. It is primarily used to prevent invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation and in immunodeficient patients and potentially life-threatening infections. Voriconazole belongs to the triazole class of antifungals and is indicated for the treatment of invasive aspergillosis, non-neutropenia, severe invasive infections caused by fluconazole-resistant Candida, or severe infections caused by Actinobacillus foot fungi and Fusarium oxysporum, in adults and pediatric patients over 2 years of age. When using voriconazole tablets for treatment, electrolyte changes should be monitored in a timely manner, if the patient has hypocalcemia, hypokalemia and other electrolyte disorders, appropriate treatment should be given in a timely manner. Common adverse reactions include visual impairment, fever, vomiting, nausea, diarrhea, dyspnea, etc. Pregnant women and patients with a history of allergy are prohibited. If the patient develops urinary tract infection, it is recommended to consult the doctor in time and take the corresponding treatment plan under the doctor’s guidance, and not to use the medicine privately.